The recent development of potent and highly specific Kac competitive inhibitors for BET BRDs provides a compelling case for targeting these BRDs for the treatment of an extremely aggressive subtype of squamous cell carcinoma that is caused by chromosomal rearrangement of BRD3 or BRD4 with NUT (Filippakopoulos et al., 2010; French, 2010b). This evidence concerns the gene NUTM1 and squamous cell carcinoma.